Hemophilia B Drugs Market Set for Transformative Growth by 2034, Predicts DelveInsight

The hemophilia B market is steadily advancing, driven by evolving treatment strategies and ongoing research. DelveInsight's latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics.
DelveInsight's "Hemophilia B - Market Insight, Epidemiology, And Market Forecast - 2034 [https://www.delveinsight.com/report-store/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] report offers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Some of the key facts of the Hemophilia B Market Report:

- According to DelveInsight, the market for Hemophilia B in the 7MM is expected to witness notable growth during the study period from 2020 to 2034.

- In 2023, the US had the highest diagnosed prevalent cases of Hemophilia B among the 7MM, with around 4K cases, expected to rise during the forecast period.

- Among EU4 and the UK, France reported the highest cases, while Germany had the lowest.

- In the US, Hemophilia B was most common in the 19-44 age group, comprising about 35% of total cases.

- In December 2024, Novo announced that the FDA approved concizumab, its tissue factor pathway inhibitor (TFPI) antagonist, as a once-daily treatment to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A or B with inhibitors.

- In October 2024, Pfizer Inc. announced that the FDA has approved HYMPAVZI Trademark (marstacimab-hncq) for routine prophylaxis in adults and pediatric patients aged 12 and older with hemophilia A or B, without FVIII or FIX inhibitors.

- In October 2024, Novo Nordisk received support from European regulators for the approval of its anti-TFPI antibody, Alhemo (concizumab), as a preventive treatment for hemophilia. The company stated that, if approved, this therapy would provide the first subcutaneous prophylactic treatment to be administered once daily for individuals with hemophilia A or B who have inhibitors.

- Emerging hemophilia B drugs include Fitusiran, Marstacimab, SerpinPC, and others.

- Leading companies in the Hemophilia B market include UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme, a Sanofi Company, Alnylam Pharmaceuticals, Novo Nordisk, Pfizer, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, Sangamo Therapeutics, and others.

- The rising number of radiation therapy patients and advancements in therapeutic options continue to drive the demand for effective Hemophilia B treatments.

To know in detail about the Hemophilia B market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Hemophilia B Market Forecast [https://www.delveinsight.com/report-store/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Hemophilia B Overview

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by a deficiency of factor IX, a crucial clotting protein needed for blood coagulation. The severity of the condition depends on the levels of factor IX in the blood. While there is no cure, treatment focuses on managing symptoms and enhancing quality of life. Ongoing research aims to develop advanced therapies and improve disease understanding.

Get a Free sample for the Hemophilia B Market Report: https://www.delveinsight.com/report-store/hemophilia-b-market [https://www.delveinsight.com/report-store/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Hemophilia B Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hemophilia B Epidemiology Segmentation:

The Hemophilia B epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

- Total Diagnosed Prevalent Cases of Hemophilia B in the 7MM

- Severity-Specific Prevalent Cases of Hemophilia B in the 7MM

- Age-Specific Prevalent Cases of Hemophilia B in the 7MM

- Prevalent Cases of Hemophilia B with or without Inhibitors in the 7MM

- Treated Patient Pool of Hemophilia B in the 7MM

Download the report to understand which factors are driving Hemophilia B epidemiology trends @ Hemophilia B Epidemiology Forecast [https://www.delveinsight.com/report-store/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Hemophilia B Drugs Uptake, and Pipeline Development Activities

The Hemophilia B drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to be launched during the study period. The analysis covers the Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hemophilia B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hemophilia B Market Strengths

- Continuous innovation in hemophilia B drugs, including gene therapies and extended half-life treatments, is improving patient outcomes and reducing treatment burden. These advancements drive market growth by offering more effective and long-lasting solutions.

- The hemophilia B market benefits from a robust pipeline of novel therapies, with multiple drug candidates receiving regulatory approvals. The introduction of breakthrough treatments enhances market expansion and provides patients with more therapeutic options.

Hemophilia B Market Weaknesses

- Hemophilia B drugs, particularly gene therapies and recombinant factor IX treatments, are expensive, limiting access for many patients. The high cost of lifelong treatment poses a significant economic burden on healthcare systems and individuals.

- Despite advancements, hemophilia B remains underdiagnosed in many regions due to limited awareness and access to specialized healthcare. Delayed diagnosis and inadequate treatment can lead to severe complications, impacting disease management and market penetration.

Scope of the Hemophilia B Market Report

- Study Period: 2020-2034

- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

- Key Hemophilia B Therapies: Fitusiran, Marstacimab, SerpinPC, and others.

- Key Hemophilia B Companies: UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme, a Sanofi Company, Alnylam Pharmaceuticals, Novo Nordisk, Pfizer, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, Sangamo Therapeutics, and others.

- Hemophilia B Therapeutic Assessment: Hemophilia B currently marketed and Hemophilia B emerging therapies

- Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers

- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

- Hemophilia B Unmet Needs, KOL's views, Analyst's views, Hemophilia B Market Access and Reimbursement

To learn more about the key players and advancements in the Hemophilia B Treatment Landscape, visit the Hemophilia B Market Analysis Report [https://www.delveinsight.com/report-store/hemophilia-b-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Table of Contents

1. Hemophilia B Market Report Introduction

2. Executive Summary for Hemophilia B

3. SWOT analysis of Hemophilia B

4. Hemophilia B Patient Share (%) Overview at a Glance

5. Hemophilia B Market Overview at a Glance

6. Hemophilia B Disease Background and Overview

7. Hemophilia B Epidemiology and Patient Population

8. Country-Specific Patient Population of Hemophilia B

9. Hemophilia B Current Treatment and Medical Practices

10. Hemophilia B Unmet Needs

11. Hemophilia B Emerging Therapies

12. Hemophilia B Market Outlook

13. Country-Wise Hemophilia B Market Analysis (2020-2034)

14. Hemophilia B Market Access and Reimbursement of Therapies

15. Hemophilia B Market Drivers

16. Hemophilia B Market Barriers

17. Hemophilia B Appendix

18. Hemophilia B Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hemophilia-b-drugs-market-set-for-transformative-growth-by-2034-predicts-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.